Lantheus launches MR angio agent in Canada
Diagnostic imaging company Lantheus Medical Imaging has launched its injectable MR angiography (MRA) blood pool imaging agent, Ablavar, in Canada.
According to the North Billerica, Mass.-based company, the product is indicated for contrast-enhanced MRA for visualization of abdominal or limb vessels in patients with suspected or known vascular disease. The agent was previously marketed in Canada as Vasovist.
Ablavar was released in the U.S. in January, and is indicated for the evaluation of aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease in the U.S., Lantheus added.
According to the North Billerica, Mass.-based company, the product is indicated for contrast-enhanced MRA for visualization of abdominal or limb vessels in patients with suspected or known vascular disease. The agent was previously marketed in Canada as Vasovist.
Ablavar was released in the U.S. in January, and is indicated for the evaluation of aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease in the U.S., Lantheus added.